These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34378436)

  • 1. Preclinical
    Kang MS; Shin M; Ottoy J; Aliaga AA; Mathotaarachchi S; Quispialaya K; Pascoal TA; Collins DL; Chakravarty MM; Mathieu A; Sandelius Å; Blennow K; Zetterberg H; Massarweh G; Soucy JP; Cuello AC; Gauthier S; Waterston M; Yoganathan N; Lessard E; Haqqani A; Rennie K; Stanimirovic D; Chakravarthy B; Rosa-Neto P
    J Cereb Blood Flow Metab; 2022 May; 42(5):788-801. PubMed ID: 34378436
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog.
    Lessard E; Rennie K; Haqqani A; Ling B; Whitfield J; Paradis A; Araujo J; Yoganathan N; Gillard J; Stanimirovic D; Chakravarthy B
    Pharm Res; 2022 Jul; 39(7):1497-1507. PubMed ID: 35704250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.
    Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P
    J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.
    Cantillon M; Andreasen N; Prins N
    J Prev Alzheimers Dis; 2024; 11(1):65-70. PubMed ID: 38230718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
    Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
    Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Mutlu J; Landeau B; Gaubert M; de La Sayette V; Desgranges B; Chételat G
    Brain; 2017 Dec; 140(12):3317-3328. PubMed ID: 29194503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.
    Jiang C; Wang Q; Xie S; Chen Z; Fu L; Peng Q; Liang Y; Guo H; Guo T;
    Brain Commun; 2022; 4(2):fcac084. PubMed ID: 35441134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.
    Maya Y; Okumura Y; Kobayashi R; Onishi T; Shoyama Y; Barret O; Alagille D; Jennings D; Marek K; Seibyl J; Tamagnan G; Tanaka A; Shirakami Y
    Brain; 2016 Jan; 139(Pt 1):193-203. PubMed ID: 26490333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.